{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039338","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.742914+00:00","generated_at":"2026-06-12T02:13:50.311305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics Q2 net loss $51M; suspends CRN04777; paltusotine Phase 3 data due Sept 2023","bullets":["Net loss $51.0M on revenue $1.0M (vs. $42.4M loss on $0.4M revenue in Q2 2022).","Cash, equivalents, investments $264.5M as of June 30, 2023 (down from $334.4M at Dec 31, 2022).","Phase 3 PATHFNDR-1 paltusotine topline data expected September 2023; PATHFNDR-2 enrollment complete, data in Q1 2024.","CRN04777 development suspended after nonclinical findings eroded anticipated therapeutic margins; not related to other candidates.","Paltusotine NDA submission anticipated in 2024 pending successful PATHFNDR data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039338","json":"https://secwatch.observer/filing/0000950170-23-039338.json","markdown":"https://secwatch.observer/filing/0000950170-23-039338.md","text":"https://secwatch.observer/filing/0000950170-23-039338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/0000950170-23-039338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/crnx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:13:50.311305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b49366f11b763699a6e44dc0dbe807096fab57f","claim":"Crinetics Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million, net income Net loss of $51.0 million.","evidence_excerpt":"of $2.7 million. • Net loss for the three months ended June 30, 2023, was $51.0 million, compared to a net loss of $42.4 million for the same period in 2022. • Revenues were $1.0 million for the three months ended June 30, 2023, compared to $0.4 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine licensing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017023039338/0000950170-23-039338-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"Net loss of $51.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}